Scaling Solutions in Denmark: Overview, Access & Go-to-Market

Join us for another event in our BD Network series! This time, we will be focusing on everything you need to know to scale in Denmark.

Navigating the complexities of scaling in Denmark requires strong evidence generation and a solid health economic strategy. This session will equip you with best practices and insights to ensure your solution is cost-effective, scalable, and attractive to decision-makers.

This exclusive event is designed to equip healthtech companies with the tools, strategies, and insights needed to build a strong business case for their solutions - one that resonates with payers, hospitals, and municipalities.

What to Expect:
Gain a solid understanding of Denmark’s healthcare structure, innovation priorities, and the broader life science ecosystem. Anthony will provide clear insights into public reimbursement models, funding pathways, and emerging trends like value-based care. You'll also learn about key stakeholders and decision-makers, and how to navigate HTA requirements, including the growing role of real-world evidence. Finally, discover common market entry challenges, success factors, and practical strategies for commercialization and stakeholder engagement in the Danish health market.

About the Expert:

Anthony Christos Roumeliotis is a seasoned healthcare professional with over five years of experience as a pharmacist and five years in market access consulting. Currently serving as a Principal Consultant at NHTA, he specializes in leading clients through the complex Nordic pricing and reimbursement landscape and has worked across multiple therapy areas. His technical expertise includes conducting systematic literature reviews, meta-analyses, and indirect treatment comparisons to support evidence-based market access strategies.He is also experienced in leading key opinion leader (KOL) and payer interviews, performing in-depth landscape analyses, addressing target product profile (TPP) challenges, and navigating global HTA and payer objections related to clinical trial design and market access strategy. With a strong academic foundation in pharmacology, epidemiology, and biostatistics, Anthony effectively bridges scientific evidence with strategic health policy and reimbursement decision-making.

Criteria for joining this event:
- You are a paying member of Health Tech Hub Copenhagen (HTHC).

If you are not yet a member and would like to find out more about the opportunities available at HTHC, please contact Line (line@healthtechhub.org)